This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2006;296:270.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Atlanta—In their continued search for new and effective treatments for cancer, scientists investigating the potential of novel targeted therapies reported results of several early trials at the recent annual meeting of the American Society of Clinical Oncology held here in June.

"The research . . . is exciting not only because it shows how far we have come in understanding the disease itself, but because it demonstrates the success in translating this knowledge into practice," said Bruce Johnson, MD, of the Dana-Farber Cancer Institute, in Boston.

AGENTS OF APOPTOSIS

In a phase 1 trial, an agent that binds to receptors on cancer cells that trigger apoptosis, or cell death, halted cancer growth in more than half of the patients whose tumors could be assessed. This recombinant, or genetically engineered, human Apo2L/TRAIL (Apo2L) targets two cell death receptors called DR4 and DR5.

In this trial, 58 patients with different types of advanced cancers received . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mechanisms of Mitotic Cell Death Induced by Chemotherapy-Mediated G2 Checkpoint Abrogation
Vogel et al.
Cancer Res. 2007;67:339-345.
ABSTRACT | FULL TEXT